1. Lonn ЕМ, Yusuf S, Jha Р et al. Emerging role of angiotensin-converting-enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90: 2056–69.
2. Svensson P, de Faire U, Sleight P et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001; 38 (6): E28–32.
3. Schulman SP, Becker LC, Kass DA et al. L-arginine therapy in acute myocardial infarction. The vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295: 58–64.
4. Borhani NO, Mercuri M, Borhani PA et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276 (10): 785–91.
5. Yusuf S, Dagenais G, Pogue J et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342 (3): 154–60.
6. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation. Study Investigators N Engl J Med 2000; 342: 145–53.
7. The EURopean trial On reduction of cardiac events with Perindipril in Stable coronary Artery dis-ease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 2003.
8. Bosch J, Lonn E, Pogue J et al. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112 (9): 1339–46.
9. Lonn E, Yusuf S, Dzavik V et al. SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103 (7): 919–25.
10. Curt D. Furberg: «Class effects and evidence-based medicine». Clin Cardiol 2000; 23 (Suppl. IV): IV–15.
11. Anderson TJ, Overhiser RW, Haber H, Charbonneau F. A comparative study of four anti-hypertensive agents on endothelial function in patients with coronary disease. J Am Coll Cardiol 1998; 31 (2 Suppl. A): 327 A. Abstract.
12. Grandaliano G, Ranieri E, Monno R et al. Ramipril inhibits in vitro human mesangial cell proliferation and platelet-derived growth factor expression. Exp Nephrol 1999; 7 (3): 229–35.
13. Bönner G. The role of kinins in the antihypertensive and cardioprotective effects of ACE inhibitors. Drugs 1997; 54 (Suppl. 5): 23–30.
14. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35 (1): 60–6.
15. Pitt B, O'Neill B, Feldman R et al. QUIET Study Group. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001; 87 (9): 1058–63.
16. Yusuf S. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342 (3): 145–53.
17. Обучающие материалы University of Minnesota College of Pharmacy, Minneapolis https://sites.google.com/a/umn.edu/phar6122/case-examples/mega-case/answer-2/answer/ace-inhibitor
18. Consumer Reports: best-buy-drugs. http://www.consumerreports.org/health/best-buy-drugs/ace-inhibitors.htm.
19. HOPE study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 2000; 355: 253–9.
20. Диагностика и лечение артериальной гипертензии. Третий пересмотр рекомендаций ВНОК и РМОАГ. Кардиоваск. терапия и профилактика. 2008; 7 (6), прил. 2: 1–32.
21. Диагностика и лечение хронической сердечной недостаточности. Национальные рекомендации ВНОК и ОССН (второй пересмотр). Сердечная недостаточность. 2007; 8 (2): 1–35.
22. Кардиоваскулярная профилактика. Национальные рекомендации ВНОК. Кардиоваск. терапия и профилактика. 2011; 10 (6), прил. 2.
23. Диагностика и лечение стабильной стенокардии. Рекомендации ВНОК (второй пересмотр).  Под ред. Р.Г.Оганова, М.Н.Мамедова. Национ. клин. рекомендации. М.: МЕДИ Экспо, 2009; с. 37–76.
24. Государственный реестр лекарственных средств http://grls.rosminzdrav.ru/grls.aspx?s=%u0440%u0430%u043c%u0438%u043f%u0440%u0438%u043b.

Н.А.Ваулин 

ГБУЗ Городская клиническая больница №29 им. Н.Э.Баумана Департамента здравоохранения г. Москвы